GlassScriptPhysician profile
Luke P Lemke
NPI 1104820489
$1,984.47
in general payments reported to CMS, 2019-2025
25 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $187 · 2021: $308 · 2022: $197 · 2023: $307 · 2024: $236 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.11 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $359.83 | 2019-2024 | Airsupra, Xigduo |
| Novo Nordisk INC | $283.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $200.87 | 2019-2020 | |
| Amgen INC. | $190.64 | 2019-2023 | Repatha |
| Lilly USA, LLC | $151.95 | 2020-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $113.88 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.95 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.61 | 2020-2025 | Jardiance |
| Abbvie INC. | $79.40 | 2021-2025 | |
| Abbott Laboratories | $59.87 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $42.48 | 2020-2024 | Bexsero |
| Xeris Pharmaceuticals, INC. | $40.17 | 2022-2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $33.85 | 2023-2025 | Gemtesa |
| Baxter Healthcare | $28.62 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $27.74 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.19 | 2022 | |
| Merck Sharp & Dohme LLC | $26.29 | 2022-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2021 | |
| Inspire Medical Systems, INC. | $22.64 | 2025 | Inspire |
| Depuy Synthes Sales INC. | $15.92 | 2019 | |
| Esperion Therapeutics, INC. | $15.64 | 2024 | Nexletol |
| Medicure Pharma INC. | $15.07 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Lemke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.